Emotion regulation group therapy for deliberate self-harm: a multi-site evaluation in routine care using an uncontrolled open trial design
Open accessThe DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index; 2 of the 33 sources its claims cite were checked for support.
Abstract
Objective Emotion regulation group therapy (ERGT) has shown promising results in several efficacy trials. However, it has not been evaluated outside a research setting. In order to increase the availability of empirically supported treatments for individuals with borderline personality disorder and deliberate self-harm, an evaluation of ERGT in routine clinical care was conducted with therapists of different professional backgrounds who had received brief intensive training in ERGT prior to trial onset. Design Multi-site evaluation, using an uncontrolled open trial design with assessments at pretreatment, post-treatment and 6-month follow-up. Setting 14 adult outpatient psychiatric clinics across Sweden. Participants Ninety-five women (mean age=25.1 years) with borderline personality disorder (both threshold and subthreshold) and repeated self-harm were enrolled in the study. Ninety-three per cent of participants completed the post-treatment assessment and 88% completed the follow-up assessment. Primary and secondary outcome measures Primary outcome was self-harm frequency as measured with the Deliberate Self-Harm Inventory. Secondary outcomes included self-harm versatility, emotion dysregulation, other self-destructive behaviours, depression, anxiety, stress symptoms and interpersonal and vocational difficulties. Intervention ERGT is an adjunctive, 14-week, acceptance-based behavioural group treatment that directly targets both self-harm and its proposed underlying mechanism of emotion dysregulation. Results At post-treatment, intent-to-treat analyses revealed a significant improvement associated with a moderate effect size on the primary outcome of self-harm frequency (51%, reduction; Cohen's d=0.52, p<0.001) as well as significant improvements in the secondary outcomes of self-harm versatility, emotion dysregulation, other self-destructive behaviours and general psychiatric symptomatology. These results were either maintained or further improved on at 6-month follow-up. Conclusions ERGT appears to be a feasible, transportable and useful treatment for deliberate self-harm and other self-destructive behaviours, emotion dysregulation and psychiatric symptoms when delivered by clinicians in the community. Trial registration number NCT01986257; results. © Article author(s) 2017.
Overview
CoChat Summary
## TL;DR
Emotion regulation group therapy (ERGT) was evaluated in routine care across 14 Swedish outpatient psychiatric clinics in an uncontrolled open trial with 95 women with BPD and repeated self-harm. The study found significant improvements in self-harm and several related outcomes through post-treatment and 6-month follow-up, but the authors caution that the lack of a control group prevents causal conclusions.
## Key findings
- Primary outcome: self-harm frequency fell by 51% from pretreatment to post-treatment in intent-to-treat analyses, with Cohen’s d = 0.52, p < 0.001; by 6-month follow-up the reduction was 76% and effect size was d = 0.99 from pretreatment to follow-up.
- The proportion with zero DSH episodes increased from 4.2% at pretreatment to 17.9% at post-treatment and 25.3% at 6-month follow-up; both increases were statistically significant.
- Secondary outcomes improved significantly for self-harm versatility, emotion dysregulation, other self-destructive behaviours, depression, and stress symptoms at post-treatment, and these gains were maintained or further improved at follow-up.
- Improvements in interpersonal difficulties and social/vocational impairment were not significant at post-treatment but were significant by 6-month follow-up.
## Methods
- Design: Multi-site, uncontrolled open trial with assessments at pretreatment, post-treatment, and 6-month follow-up.
- Sample/data: 95 women (mean age 25.1 years) with threshold or subthreshold BPD and repeated self-harm, recruited from 14 adult outpatient psychiatric clinics across Sweden; 93% completed post-treatment and 88% completed follow-up.
- Analysis: Intent-to-treat analyses using random effects modelling in R; negative binomial generalised mixed models for count outcomes (DSH frequency, BSL) and linear models for continuous outcomes, with sensitivity analyses for clinic clustering, concurrent medication, treatment as usual, and session attendance.
## Limitations
- The paper explicitly states that the lack of a control condition prevents conclusions about the effects of ERGT versus treatment as usual or time alone.
- The authors note that no systematic adherence ratings were conducted, limiting conclusions about treatment fidelity and its relation to outcomes.
- The study relied solely on self-report measures and included only women, limiting generalisability to men; the paper also notes that excluding those with current substance dependence may have limited external validity for the broader BPD population.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
2 Valid · 0 Not valid · 23 Not checked · 37 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“These results are consistent with past findings that characteristics of participants’ ongoing therapy in the community had minimal impact on treatment response to ERGT43 and suggest that it is engagement in ERGT rather than other (non-specific) treatment-related factors that influences reductions in DSH frequency.”
§ Emotion regulation group therapy for deliberate self-harm: a multi-site evaluation in routine care using an uncontrolled open trial design > Discussion The present multi-site evaluation of ERGT in routine clinical care provides additional support for the feasibility and transportability of this treatment. Results revealed significant improvements in DSH frequency and versatility, emotion dysregulation, self-destructive behaviours and depression and stress symptoms from pretreatment to post-treatment. By the 6-month follow-up, interpersonal difficulties and social and vocational impairment had also improved significantly. Moreover, all gains found at post-treatment were either maintained or further improved on at follow-up. Notably, the results of the sensitivity analyses strengthen our confidence in these findings, providing evidence of a significant effect of session attendance, but not treatment clinic, concurrent medication use or type of treatment as usual, on improvements in DSH frequency. These results are consistent with past findings that characteristics of participants’ ongoing therapy in the community had minimal impact on treatment response to ERGT43 and suggest that it is engagement in ERGT rather than other (non-specific) treatment-related factors that influences reductions in DSH frequency. Nonetheless, the uncontrolled open trial design precludes conclusions regarding the causal relation of treatment participation to symptom improvement as there may be other factors underlying both treatment completion status and symptom improvement (ie, motivation for treatment or alliance with treatment providers) that may, at least in part, account for the present findings. Although the results of this study need to be interpreted with caution (due to the lack of a control group), they are similar to those obtained in previous ERGT efficacy trials.11 12 Likewise, our findings of either stability or further improvements during the follow-up period are consistent with the observed pattern of continued or maintained improvement during a 9-month follow-up period in Gratz and colleagues’ randomised controlled trial (RCT).12 These findings provide further support for the durability of improvements following this relatively brief and non-intensive treatment, suggesting that participants may experience durable gains through ERGT even when delivered by community clinicians with only brief training in this treatment. Despite these similarities with previous ERGT trials, the pattern of findings for measures of interpersonal, social and vocational functioning differed from Gratz and colleagues’ previous ERGT studies.12 20 Specifically, results revealed no significant changes in interpersonal difficulties or social and vocational impairment from pretreatment to post-treatment, although there were significant (although small) improvements in these areas during the follow-up period. Although the differences in these findings may be due to study-related differences in therapist training and/or treatment delivery, they may also be explained (in part) by the fact that more than one-third of participants (39%) in the present trial were on disability pension or current sick leave, thus limiting their social interactions and vocational opportunities during treatment. Notably, rates of abstinence from DSH increased significantly from pretreatment to post-treatment, as well as from post-treatment through the 6-month follow-up, with 25.2% of participants reporting abstinence from DSH 6 months post-treatment. Nonetheless, it warrants mention that the proportion of participants reaching abstinence from DSH was lower than in previous ERGT trials.12 20 This may be due to differences in the level of training and supervision provided in this trial versus previous trials. Indeed, ratings of treatment credibility and expectancy in this trial were somewhat lower than in previous studies of ERGT, potentially capturing the lesser experience of the therapists in this trial. Conversely, the lower rate of treatment-related abstinence from DSH observed in this study may reflect differences in sample composition and/or clinical severity (as both emotion dysregulation and DSH frequency reported in this sample were at the high end of the range reported in past ERGT studies). Nonetheless, past research examining predictors of treatment response to ERGT found that several indicators of greater severity in domains relevant to ERGT (ie, baseline emotion dysregulation and BPD criteria, lifetime and recent DSH, and past-year hospitalisation and suicide attempts) predicted better responses during treatment and follow-up,43 suggesting that greater severity in certain domains may be associated with better response to this treatment. Future research is needed to clarify the particular patients most likely to benefit from ERGT. Importantly, we found significant reductions across all assessment points in DSH versatility (ie, a marker of DSH severity associated with future suicide risk).29 This finding lends support to the potential utility of ERGT in decreasing risk for self-injurious behaviours in general. Indeed, given the high occurrence of DSH and suicidal behaviours,9 as well as evidence that DSH is one of the strongest prospective predictors of future suicide attempts,44 45 the emphasis within ERGT on reducing DSH could be expected to reduce suicidal risk as well. Nonetheless, in the absence of data in this or previous ERGT trials on suicidal outcomes in particular, the benefits of ERGT for suicidality remain unknown and in need of future investigation. Although results of this study provide preliminary support for the utility of ERGT in routine clinical care, they also highlight more broadly the potential utility of targeting emotion dysregulation in the treatment of BPD-related pathology. Notably, there are several other empirically supported treatments for BPD and related pathology that directly target emotion dysregulation, including DBT6 and Systems Training for Emotional Predictability and Problem Solving.46 Findings of the efficacy of those treatments for BPD,24 46 47 combined with both the results of the current study and past findings supporting the efficacy of ERGT for DSH within BPD,11 12 highlight the potential benefits of interventions aimed at promoting adaptive emotion regulation among individuals with BPD and provide further support for emotion dysregulation as a primary mechanism underlying the pathogenesis and effective treatment of BPD and related pathology.48 There are several strengths of this study that are worth noting. First, the naturalistic design of this study permitted inclusion of a large sample of participants who received this ERGT as part of their standard treatment. Second, data attrition was low (8% at post-treatment and 18% at follow-up) and participant dropout was within expected levels when treating individuals with BPD49 and consistent with previous ERGT trials.12 Third, contrary to previous ERGT trials,11 12 20 the group leaders were of different professional backgrounds and representative of the community clinicians who regularly treat this patient population, providing support for the generalisability and transportability of this treatment. Finally, our data provide support for the feasibility of disseminating ERGT to community clinicians, as therapists in this study were provided with only readings and a brief workshop on ERGT prior to its delivery. Despite these strengths, findings must be considered in light of limitations present. First, the lack of a control condition precludes conclusions about the effects of this ERGT (vs treatment as usual or the passage of time). However, it is important to note that the waitlist conditions in previous ERGT trials generally evidenced stability over time on all measures of interest (likely due to the relatively short time-frame of the treatment period). Nonetheless, future studies are needed to evaluate the effectiveness of ERGT within an RCT design. Second, even though the participating clinicians were offered weekly supervision based on filmed sessions, no systematic adherence ratings were conducted. This limits our ability to speak to the quality of ERGT and its relation to outcome. Third, the results relied solely on self-report measures and not clinician-rated outcomes. However, research on self-reported versus clinician-rated outcomes in psychotherapy studies suggests that the use of self-report measures often results in smaller effect sizes when compared with clinician-administered instruments.50 Thus, it is possible that our results may be conservative estimates of improvements during and after treatment. Fourth, our study only included women, which limits the generalisability of the results to men. Future research is needed that evaluates ERGT within male or mixed-gender samples. Finally, current (past month) substance dependence was an exclusion criterion in this study, both to ensure comparability with previous ERGT trials and because active substance dependence requires specialised treatment and a higher level of care. Indeed, in Sweden, individuals with ongoing substance dependence are not necessarily offered treatment within a psychiatric clinic; rather, they may be referred to specialised substance dependence treatment centres. Thus, it is unlikely that the exclusion of such individuals negatively affected the generalisability of this sample to a typical Swedish psychiatric clinic. Furthermore, this criterion did not exclude individuals with past (or even recent) substance use problems. Nonetheless, given the high co-occurrence of substance dependence and BPD,51 excluding these individuals may have limited the external validity of the sample to patients with BPD as a whole. Despite these limitations, our results provide further evidence for the utility and transportability of ERGT, suggesting that this is a feasible treatment for DSH, emotion dysregulation and psychiatric symptoms when delivered by community clinicians in traditional clinical settings.
What the sources say
- Supportedcites [43] source
The Discussion reports that characteristics of participants’ ongoing community therapy had minimal impact on response to ERGT; therapist orientation did not influence any outcome, and therapy intensity largely did not affect response. The sentence presents the further claim about engagement in ERGT as the citing authors’ inference, not as a finding attributed to this source. Page numbers are not available in the supplied passages. (LLM, conf=0.94)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Nonetheless, past research examining predictors of treatment response to ERGT found that several indicators of greater severity in domains relevant to ERGT (ie, baseline emotion dysregulation and BPD criteria, lifetime and recent DSH, and past-year hospitalisation and suicide attempts) predicted better responses during treatment and follow-up,43”
§ Emotion regulation group therapy for deliberate self-harm: a multi-site evaluation in routine care using an uncontrolled open trial design > Discussion The present multi-site evaluation of ERGT in routine clinical care provides additional support for the feasibility and transportability of this treatment. Results revealed significant improvements in DSH frequency and versatility, emotion dysregulation, self-destructive behaviours and depression and stress symptoms from pretreatment to post-treatment. By the 6-month follow-up, interpersonal difficulties and social and vocational impairment had also improved significantly. Moreover, all gains found at post-treatment were either maintained or further improved on at follow-up. Notably, the results of the sensitivity analyses strengthen our confidence in these findings, providing evidence of a significant effect of session attendance, but not treatment clinic, concurrent medication use or type of treatment as usual, on improvements in DSH frequency. These results are consistent with past findings that characteristics of participants’ ongoing therapy in the community had minimal impact on treatment response to ERGT43 and suggest that it is engagement in ERGT rather than other (non-specific) treatment-related factors that influences reductions in DSH frequency. Nonetheless, the uncontrolled open trial design precludes conclusions regarding the causal relation of treatment participation to symptom improvement as there may be other factors underlying both treatment completion status and symptom improvement (ie, motivation for treatment or alliance with treatment providers) that may, at least in part, account for the present findings. Although the results of this study need to be interpreted with caution (due to the lack of a control group), they are similar to those obtained in previous ERGT efficacy trials.11 12 Likewise, our findings of either stability or further improvements during the follow-up period are consistent with the observed pattern of continued or maintained improvement during a 9-month follow-up period in Gratz and colleagues’ randomised controlled trial (RCT).12 These findings provide further support for the durability of improvements following this relatively brief and non-intensive treatment, suggesting that participants may experience durable gains through ERGT even when delivered by community clinicians with only brief training in this treatment. Despite these similarities with previous ERGT trials, the pattern of findings for measures of interpersonal, social and vocational functioning differed from Gratz and colleagues’ previous ERGT studies.12 20 Specifically, results revealed no significant changes in interpersonal difficulties or social and vocational impairment from pretreatment to post-treatment, although there were significant (although small) improvements in these areas during the follow-up period. Although the differences in these findings may be due to study-related differences in therapist training and/or treatment delivery, they may also be explained (in part) by the fact that more than one-third of participants (39%) in the present trial were on disability pension or current sick leave, thus limiting their social interactions and vocational opportunities during treatment. Notably, rates of abstinence from DSH increased significantly from pretreatment to post-treatment, as well as from post-treatment through the 6-month follow-up, with 25.2% of participants reporting abstinence from DSH 6 months post-treatment. Nonetheless, it warrants mention that the proportion of participants reaching abstinence from DSH was lower than in previous ERGT trials.12 20 This may be due to differences in the level of training and supervision provided in this trial versus previous trials. Indeed, ratings of treatment credibility and expectancy in this trial were somewhat lower than in previous studies of ERGT, potentially capturing the lesser experience of the therapists in this trial. Conversely, the lower rate of treatment-related abstinence from DSH observed in this study may reflect differences in sample composition and/or clinical severity (as both emotion dysregulation and DSH frequency reported in this sample were at the high end of the range reported in past ERGT studies). Nonetheless, past research examining predictors of treatment response to ERGT found that several indicators of greater severity in domains relevant to ERGT (ie, baseline emotion dysregulation and BPD criteria, lifetime and recent DSH, and past-year hospitalisation and suicide attempts) predicted better responses during treatment and follow-up,43 suggesting that greater severity in certain domains may be associated with better response to this treatment. Future research is needed to clarify the particular patients most likely to benefit from ERGT. Importantly, we found significant reductions across all assessment points in DSH versatility (ie, a marker of DSH severity associated with future suicide risk).29 This finding lends support to the potential utility of ERGT in decreasing risk for self-injurious behaviours in general. Indeed, given the high occurrence of DSH and suicidal behaviours,9 as well as evidence that DSH is one of the strongest prospective predictors of future suicide attempts,44 45 the emphasis within ERGT on reducing DSH could be expected to reduce suicidal risk as well. Nonetheless, in the absence of data in this or previous ERGT trials on suicidal outcomes in particular, the benefits of ERGT for suicidality remain unknown and in need of future investigation. Although results of this study provide preliminary support for the utility of ERGT in routine clinical care, they also highlight more broadly the potential utility of targeting emotion dysregulation in the treatment of BPD-related pathology. Notably, there are several other empirically supported treatments for BPD and related pathology that directly target emotion dysregulation, including DBT6 and Systems Training for Emotional Predictability and Problem Solving.46 Findings of the efficacy of those treatments for BPD,24 46 47 combined with both the results of the current study and past findings supporting the efficacy of ERGT for DSH within BPD,11 12 highlight the potential benefits of interventions aimed at promoting adaptive emotion regulation among individuals with BPD and provide further support for emotion dysregulation as a primary mechanism underlying the pathogenesis and effective treatment of BPD and related pathology.48 There are several strengths of this study that are worth noting. First, the naturalistic design of this study permitted inclusion of a large sample of participants who received this ERGT as part of their standard treatment. Second, data attrition was low (8% at post-treatment and 18% at follow-up) and participant dropout was within expected levels when treating individuals with BPD49 and consistent with previous ERGT trials.12 Third, contrary to previous ERGT trials,11 12 20 the group leaders were of different professional backgrounds and representative of the community clinicians who regularly treat this patient population, providing support for the generalisability and transportability of this treatment. Finally, our data provide support for the feasibility of disseminating ERGT to community clinicians, as therapists in this study were provided with only readings and a brief workshop on ERGT prior to its delivery. Despite these strengths, findings must be considered in light of limitations present. First, the lack of a control condition precludes conclusions about the effects of this ERGT (vs treatment as usual or the passage of time). However, it is important to note that the waitlist conditions in previous ERGT trials generally evidenced stability over time on all measures of interest (likely due to the relatively short time-frame of the treatment period). Nonetheless, future studies are needed to evaluate the effectiveness of ERGT within an RCT design. Second, even though the participating clinicians were offered weekly supervision based on filmed sessions, no systematic adherence ratings were conducted. This limits our ability to speak to the quality of ERGT and its relation to outcome. Third, the results relied solely on self-report measures and not clinician-rated outcomes. However, research on self-reported versus clinician-rated outcomes in psychotherapy studies suggests that the use of self-report measures often results in smaller effect sizes when compared with clinician-administered instruments.50 Thus, it is possible that our results may be conservative estimates of improvements during and after treatment. Fourth, our study only included women, which limits the generalisability of the results to men. Future research is needed that evaluates ERGT within male or mixed-gender samples. Finally, current (past month) substance dependence was an exclusion criterion in this study, both to ensure comparability with previous ERGT trials and because active substance dependence requires specialised treatment and a higher level of care. Indeed, in Sweden, individuals with ongoing substance dependence are not necessarily offered treatment within a psychiatric clinic; rather, they may be referred to specialised substance dependence treatment centres. Thus, it is unlikely that the exclusion of such individuals negatively affected the generalisability of this sample to a typical Swedish psychiatric clinic. Furthermore, this criterion did not exclude individuals with past (or even recent) substance use problems. Nonetheless, given the high co-occurrence of substance dependence and BPD,51 excluding these individuals may have limited the external validity of the sample to patients with BPD as a whole. Despite these limitations, our results provide further evidence for the utility and transportability of ERGT, suggesting that this is a feasible treatment for DSH, emotion dysregulation and psychiatric symptoms when delivered by community clinicians in traditional clinical settings.
What the sources say
- Supportedcites [43] source
The Abstract states the cited claim nearly verbatim. The Results (Clinical Characteristics) specify that baseline emotion dysregulation and BPD criteria predicted greater improvement in BPD symptoms, lifetime and recent self-harm predicted continued improvement in self-harm, and past-year hospitalization and suicide attempts predicted improvement in experiential avoidance during treatment or follow-up. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Participants reported continued reductions in deliberate self-harm after treatment conclusion.”
§ Emotion regulation group therapy for deliberate self-harm: a multi-site evaluation in routine care using an uncontrolled open trial design > Abstract > Trial registration number
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The increase between post-treatment and follow-up was also significant (Exact McNemar’s χ2=7.14, df=1, p=0.01).”
§ Emotion regulation group therapy for deliberate self-harm: a multi-site evaluation in routine care using an uncontrolled open trial design > Results > Primary outcome
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Despite these similarities with previous ERGT trials, the pattern of findings for measures of interpersonal, social and vocational functioning differed from Gratz and colleagues’ previous ERGT studies.12 20”
§ Emotion regulation group therapy for deliberate self-harm: a multi-site evaluation in routine care using an uncontrolled open trial design > Discussion The present multi-site evaluation of ERGT in routine clinical care provides additional support for the feasibility and transportability of this treatment. Results revealed significant improvements in DSH frequency and versatility, emotion dysregulation, self-destructive behaviours and depression and stress symptoms from pretreatment to post-treatment. By the 6-month follow-up, interpersonal difficulties and social and vocational impairment had also improved significantly. Moreover, all gains found at post-treatment were either maintained or further improved on at follow-up. Notably, the results of the sensitivity analyses strengthen our confidence in these findings, providing evidence of a significant effect of session attendance, but not treatment clinic, concurrent medication use or type of treatment as usual, on improvements in DSH frequency. These results are consistent with past findings that characteristics of participants’ ongoing therapy in the community had minimal impact on treatment response to ERGT43 and suggest that it is engagement in ERGT rather than other (non-specific) treatment-related factors that influences reductions in DSH frequency. Nonetheless, the uncontrolled open trial design precludes conclusions regarding the causal relation of treatment participation to symptom improvement as there may be other factors underlying both treatment completion status and symptom improvement (ie, motivation for treatment or alliance with treatment providers) that may, at least in part, account for the present findings. Although the results of this study need to be interpreted with caution (due to the lack of a control group), they are similar to those obtained in previous ERGT efficacy trials.11 12 Likewise, our findings of either stability or further improvements during the follow-up period are consistent with the observed pattern of continued or maintained improvement during a 9-month follow-up period in Gratz and colleagues’ randomised controlled trial (RCT).12 These findings provide further support for the durability of improvements following this relatively brief and non-intensive treatment, suggesting that participants may experience durable gains through ERGT even when delivered by community clinicians with only brief training in this treatment. Despite these similarities with previous ERGT trials, the pattern of findings for measures of interpersonal, social and vocational functioning differed from Gratz and colleagues’ previous ERGT studies.12 20 Specifically, results revealed no significant changes in interpersonal difficulties or social and vocational impairment from pretreatment to post-treatment, although there were significant (although small) improvements in these areas during the follow-up period. Although the differences in these findings may be due to study-related differences in therapist training and/or treatment delivery, they may also be explained (in part) by the fact that more than one-third of participants (39%) in the present trial were on disability pension or current sick leave, thus limiting their social interactions and vocational opportunities during treatment. Notably, rates of abstinence from DSH increased significantly from pretreatment to post-treatment, as well as from post-treatment through the 6-month follow-up, with 25.2% of participants reporting abstinence from DSH 6 months post-treatment. Nonetheless, it warrants mention that the proportion of participants reaching abstinence from DSH was lower than in previous ERGT trials.12 20 This may be due to differences in the level of training and supervision provided in this trial versus previous trials. Indeed, ratings of treatment credibility and expectancy in this trial were somewhat lower than in previous studies of ERGT, potentially capturing the lesser experience of the therapists in this trial. Conversely, the lower rate of treatment-related abstinence from DSH observed in this study may reflect differences in sample composition and/or clinical severity (as both emotion dysregulation and DSH frequency reported in this sample were at the high end of the range reported in past ERGT studies). Nonetheless, past research examining predictors of treatment response to ERGT found that several indicators of greater severity in domains relevant to ERGT (ie, baseline emotion dysregulation and BPD criteria, lifetime and recent DSH, and past-year hospitalisation and suicide attempts) predicted better responses during treatment and follow-up,43 suggesting that greater severity in certain domains may be associated with better response to this treatment. Future research is needed to clarify the particular patients most likely to benefit from ERGT. Importantly, we found significant reductions across all assessment points in DSH versatility (ie, a marker of DSH severity associated with future suicide risk).29 This finding lends support to the potential utility of ERGT in decreasing risk for self-injurious behaviours in general. Indeed, given the high occurrence of DSH and suicidal behaviours,9 as well as evidence that DSH is one of the strongest prospective predictors of future suicide attempts,44 45 the emphasis within ERGT on reducing DSH could be expected to reduce suicidal risk as well. Nonetheless, in the absence of data in this or previous ERGT trials on suicidal outcomes in particular, the benefits of ERGT for suicidality remain unknown and in need of future investigation. Although results of this study provide preliminary support for the utility of ERGT in routine clinical care, they also highlight more broadly the potential utility of targeting emotion dysregulation in the treatment of BPD-related pathology. Notably, there are several other empirically supported treatments for BPD and related pathology that directly target emotion dysregulation, including DBT6 and Systems Training for Emotional Predictability and Problem Solving.46 Findings of the efficacy of those treatments for BPD,24 46 47 combined with both the results of the current study and past findings supporting the efficacy of ERGT for DSH within BPD,11 12 highlight the potential benefits of interventions aimed at promoting adaptive emotion regulation among individuals with BPD and provide further support for emotion dysregulation as a primary mechanism underlying the pathogenesis and effective treatment of BPD and related pathology.48 There are several strengths of this study that are worth noting. First, the naturalistic design of this study permitted inclusion of a large sample of participants who received this ERGT as part of their standard treatment. Second, data attrition was low (8% at post-treatment and 18% at follow-up) and participant dropout was within expected levels when treating individuals with BPD49 and consistent with previous ERGT trials.12 Third, contrary to previous ERGT trials,11 12 20 the group leaders were of different professional backgrounds and representative of the community clinicians who regularly treat this patient population, providing support for the generalisability and transportability of this treatment. Finally, our data provide support for the feasibility of disseminating ERGT to community clinicians, as therapists in this study were provided with only readings and a brief workshop on ERGT prior to its delivery. Despite these strengths, findings must be considered in light of limitations present. First, the lack of a control condition precludes conclusions about the effects of this ERGT (vs treatment as usual or the passage of time). However, it is important to note that the waitlist conditions in previous ERGT trials generally evidenced stability over time on all measures of interest (likely due to the relatively short time-frame of the treatment period). Nonetheless, future studies are needed to evaluate the effectiveness of ERGT within an RCT design. Second, even though the participating clinicians were offered weekly supervision based on filmed sessions, no systematic adherence ratings were conducted. This limits our ability to speak to the quality of ERGT and its relation to outcome. Third, the results relied solely on self-report measures and not clinician-rated outcomes. However, research on self-reported versus clinician-rated outcomes in psychotherapy studies suggests that the use of self-report measures often results in smaller effect sizes when compared with clinician-administered instruments.50 Thus, it is possible that our results may be conservative estimates of improvements during and after treatment. Fourth, our study only included women, which limits the generalisability of the results to men. Future research is needed that evaluates ERGT within male or mixed-gender samples. Finally, current (past month) substance dependence was an exclusion criterion in this study, both to ensure comparability with previous ERGT trials and because active substance dependence requires specialised treatment and a higher level of care. Indeed, in Sweden, individuals with ongoing substance dependence are not necessarily offered treatment within a psychiatric clinic; rather, they may be referred to specialised substance dependence treatment centres. Thus, it is unlikely that the exclusion of such individuals negatively affected the generalisability of this sample to a typical Swedish psychiatric clinic. Furthermore, this criterion did not exclude individuals with past (or even recent) substance use problems. Nonetheless, given the high co-occurrence of substance dependence and BPD,51 excluding these individuals may have limited the external validity of the sample to patients with BPD as a whole. Despite these limitations, our results provide further evidence for the utility and transportability of ERGT, suggesting that this is a feasible treatment for DSH, emotion dysregulation and psychiatric symptoms when delivered by community clinicians in traditional clinical settings.
What the sources say
- Not matchedcites 12 20
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
29 more claims
Create a free account to see all 62 claims and every source verdict.
- It may state two separate claims as one. 26
- The quote only partly states this claim. 2
- Probably not a substantial claim. 7
Statistics recomputed
Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.
- Consistentz = 11.54reported p < .001 · recomputed p < .001
“Z=11.54, p < .001”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Emotion regulation group therapy for deliberate self-harm: a multi-site evaluation in routine care using an uncontrolled open trial design > Results > Primary outcome
“The percentage of participants with an observed score of zero DSH episodes during the past 4 months increased significantly from 4.2% at pretreatment to 17.9% at post-treatment”
§ Emotion regulation group therapy for deliberate self-harm: a multi-site evaluation in routine care using an uncontrolled open trial design > Discussion
“Notably, rates of abstinence from DSH increased significantly from pretreatment to post-treatment, as well as from post-treatment through the 6-month follow-up, with 25.2% of participants reporting abstinence from DSH 6 months post-treatment.”
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
Lovibond, P. F., & Lovibond, S. H. (1995) · Behaviour Research and Therapy · doi:10.1016/0005-7967(94)00075-u · Cited by 14,523
(1998) · PubMed · Cited by 10,216
Gratz, K. L., & Roemer, L. (2004) · Journal of Psychopathology and Behavioral Assessment · doi:10.1023/b:joba.0000007455.08539.94 · Cited by 8,942
Self-citation(1993) · Cited by 7,136
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 2×
“Clinician-administered assessments at baseline included the BPD module of SCID-II,21 an interview version of DSHI,1 MINI 623 and the Columbia-Suicide Severity Rating Scale.27 Treatment outcome measures were administered in self-report format at baseline, pretreatment, post-treatment and 6-month follow-up.”
MethodAntony, M. M., Bieling, P. J., Cox, B. J., Enns, M. W., & Swinson, R. P. (1998) · Psychological Assessment · doi:10.1037/1040-3590.10.2.176 · Cited by 4,874
(1997) · American Psychiatric Press eBooks · Cited by 3,056
Cited by
Bjureberg, J., Sahlin, H., Hedman-Lagerlöf, E., Gratz, K. L., Tull, M. T., Jokinen, J., Hellner, C., & Ljótsson, B. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1885-6 · Cited by 96
The Co-occurrence of Self-Harm and Aggression: A Cognitive-Emotional Model of Dual-Harm
Shafti, M., Taylor, P. J., Forrester, A., & Pratt, D. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.586135 · Cited by 115
Bjureberg, J., Sahlin, H., Hellner, C., Hedman-Lagerlöf, E., Gratz, K. L., Bjärehed, J., Jokinen, J., Tull, M. T., & Ljótsson, B. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1527-4 · Cited by 84
Self-citationShahabi, M., Hasani, J., & Bjureberg, J. (2020) · Assessment for Effective Intervention · doi:10.1177/1534508418800210 · Cited by 48
“…disorder (Hallion et al., 2018), substance use (Fox et al., 2007), borderline personality disorder (Gratz, Tull, Baruch, Bornovalova, & Lejuez, 2008; Sahlin et al., 2017), obsessive-compulsive disorder (Yap et al., 2017), and hoarding disorder (Tolin, Levy, Wootton, Hallion, & Stevens, 2018).”
Self-citationLawlor, C., Hepworth, C., Smallwood, J., Carter, B., & Jolley, S. (2019) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.2408 · Cited by 55
Metadata
- Authors
- Sahlin, H., Bjureberg, J., Gratz, K. L., Tull, M. T., Hedman, E., Bjärehed, J., Jokinen, J., Lundh, L.-G., Ljótsson, B., & Hellner, C.
- Affiliations
- Karolinska Institutet (SE)
- University of Toledo (US)
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
- Lund University (SE)
- Corresponding author
- Sahlin, Hanna
- ORCID
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2017-10
- Volume
- 7
- Issue
- 10
- Pages
- e016220
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC5639990
- OpenAlex
- W2760895484
- Cited by
- 50
- References
- 52
- Citations by year
- 2026: 7 · 2024: 1 · 2023: 7 · 2022: 13 · 2021: 10 · 2020: 3 · 2019: 3 · 2018: 5 · 2017: 1
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DiVA at Umeå University (Umeå University) (submittedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Stockholm County Council regional research grant
- National Self-harm Project, Sweden
- Topics
- Social Sciences › Psychology › Clinical Psychology › Personality Disorders and Psychopathology
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- self-harm, borderline personality disorder, emotional dysregulation, self-destructive behaviour, depression, anxiety, stress symptoms, outpatient psychiatric care, adjunctive therapy
- MeSH terms
- Adolescent, Adult, Behavior Therapy, Borderline Personality Disorder, Emotions, Female, Humans, Middle Aged, Psychiatric Status Rating Scales, Psychotherapy, Group, Regression Analysis, Sweden, Self-Injurious Behavior, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emotion regulation group therapy for deliberate self-harm: a multi-site evaluation in routine care using an uncontrolled open trial design. https://app.cochat.ai/papers/10.1136/bmjopen-2017-016220
- The paper
- Sahlin, H., Bjureberg, J., Gratz, K. L., Tull, M. T., Hedman, E., Bjärehed, J., Jokinen, J., Lundh, L.-G., Ljótsson, B., & Hellner, C. (2017). Emotion regulation group therapy for deliberate self-harm: a multi-site evaluation in routine care using an uncontrolled open trial design. BMJ Open. https://doi.org/10.1136/bmjopen-2017-016220
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
